Targeted Therapies & Future Directives: RNAi Drug Delivery Market
                     Targeted Therapies & Future 
Directives: RNAi Drug Delivery 
Market
According to Inkwood Research, the global RNA interference (RNAi) drug delivery market is 
expected to grow at a CAGR of 22.24% over the forecast period 2024–2032. Innovations in 
pharmaceuticals have propelled RNA interference (RNAi) drug delivery to the forefront of oncology 
treatment. 
RNAi utilizes the body’s molecular mechanisms to silence disease-causing genes, offering precise 
therapeutic interventions with minimal side effects. This advancement has elevated significant 
progress in nanoparticle technologies, substantially enhancing drug delivery efficacy. Nanoparticle-
based RNAi therapies allow for targeted delivery to tumor sites while minimizing systemic side 
effects. 
Leading players like Pfizer (Germany) are pioneering nanoparticle-based RNAi therapies, focusing on
advanced cancer treatments. These innovations, in turn, reflect a commitment to integrating modern
research with industrial expertise, revolutionizing cancer therapy strategies globally.
Request a FREE sample of the RNAi Drug Delivery Market
RNAi Drug Delivery Market: Catalysts for Pharma Innovations
RNA interference (RNAi) was first discovered and described in 1998 by Andrew Fire and Craig 
Mello, leading to their Nobel Prize in Physiology in 2006. Their pioneering research demonstrated 
that double-stranded RNA (dsRNA) could silence specific genes by interfering with genetic 
expression. This breakthrough laid the foundation for RNAi to emerge as a powerful tool in molecular
biology and potential therapeutic applications.
Initially, RNA therapies focused on rare diseases but gained crucial momentum with mRNA 
vaccines during the COVID-19 pandemic, validating RNA technologies globally. This success spurred 
substantial investment and broadened development efforts into diverse therapeutic areas like 
neurology and metabolic disorders.
The evolution of RNA-based therapeutics has been intricately linked with innovations in drug delivery
systems. Early on, cationic liposomes were employed to form protective complexes with mRNA, 
shielding it from degradation. 
Liposome nanoparticles (LNPs) further emerged as sophisticated carriers, featuring lipid bilayer shells
encapsulating mRNA payloads. LNPs have demonstrated safety and efficacy in delivering RNA 
therapeutics, facilitating robust immune responses and enabling local or systemic protein expression.
Furthermore, polymers like polyethyleneimine (PEI) and poly-amido-amine (PAA) are investigated for
mRNA delivery, forming nanoparticles to improve cellular uptake and intracellular delivery 
efficiency. 
In essence, a meta-analysis of biopharma intelligence databases shows substantial trends. It includes 
commercial sales, investments, and the scope of preclinical and clinical RNA programs over the years.
Read on to discover the substantial growth in the RNA-based pharmaceuticals sphere—
 By 2022, the market capitalization of RNA-based therapies has surpassed $0.1 trillion, 
marking it as one of the fastest-growing segments in modern medicine. 
 The RNA-based companies’ market cap surged from $3 
billion in 2012 to $228 billion in 2021.
 Products like nusinersen, an ASO  treatment for spinal muscular atrophy, achieved peak 
sales of $2.1 billion in 2019. 
 Similarly, inclisiran, the first siRNA approved for treating dyslipidemia, is projected to 
reach $2.7 billion in sales by 2028. (Source)
As a result, RNA therapies are expanding, pushed by technological advancements and increasing 
confidence in their competence across a wide range of medical applications.
Click here to get more insights about the Global RNAi Drug Delivery Market
From Oncogenes to Angiogenesis: RNA Interference in Cancer Research
RNA interference (RNAi) technology has revolutionized cancer research by offering a powerful tool to
study and potentially treat various types of cancers. It operates through the silencing of specific 
genes implicated in tumorigenesis and metastasis.
One of the earliest applications of RNAi in cancer research was the targeting of oncogenes like K-Ras,
which play critical roles in promoting tumor growth. By suppressing the expression of oncogenes 
such as Bcl-2, CDK-2, Mdm-2, PKC-α, TGF-β1, H-Ras, VEGF, and GFP, RNAi has shown efficacy in 
inhibiting cancer cell proliferation.
RNA drug interference has been used to target viral oncogenes in virally induced cancers, such as 
cervical cancer (HPV) and hepatocellular carcinoma (HBV), offering potential therapeutic avenues. 
Additionally, RNAi studies on tumor suppressor genes like Rb have elucidated their roles in cancer 
progression through pathways like dE2F/dDP/RBF.
This drug interference has also been instrumental in studying DNA repair mechanisms by targeting 
genes such as Rad51, which is crucial for preventing tumor formation. It has identified nucleases 
involved in chromosomal DNA degradation and explored checkpoint responses by targeting genes 
like ATR.
In the context of cancer invasion and metastasis, RNAi-mediated inhibition of genes such 
as RECK and CXCR4 has demonstrated potential in regulating tumor cell migration and invasion. 
RNAi has further targeted angiogenesis-related proteins like VEGF and HIF, shedding light on their 
roles and potential as therapeutic targets. Moreover, RNAi is pivotal in studying anti-apoptotic genes 
like livin, Bcl-2, and xIAP, enhancing cancer cell sensitivity to traditional treatments.
In this regard, according to Inkwood Research, oncology was the major application in the global 
RNA interference (RNAi) drug delivery market in 2023.
Kindly click here to view the LinkedIn post related to this market 
Nanoparticle Formulations in RNAi Drug Delivery Industry
Nanoparticle technology serves as versatile drug carriers that can be customized to overcome the 
limitations of traditional delivery systems. The technology enables precise control over the design 
and construction of drugs, influencing their size and shape. 
By conjugating therapeutic agents, nanoscale methods create adaptable biocomposites that offer 
advantages in drug delivery and imaging. Intracellular targeting further aims to deliver drugs to 
specific sites within cells, such as tissues, organelles, or compartments. 
Market Position: As per Inkwood Research, nanoparticle drug delivery was the largest technology 
in the global RNA interference (RNAi) drug delivery market in 2023.
Moving ahead, solid, lipid and polymer-based nanoparticle delivery systems are widely used in 
pharmaceutical and biomedical industries. Leading pharmaceutical and biomedical companies 
extensively utilize these drug delivery systems to enhance therapeutic potency and targeted drug 
delivery.
Explore how top pharmaceutical companies utilize nanoparticle-based drug delivery to advance 
targeted therapies:
 Pfizer: Pfizer employs nanoparticle technology in products like Abraxane for cancer 
therapies. It enhances chemotherapy delivery directly to tumors while reducing systemic 
side effects.
 Merck: Merck utilizes nanoparticles in Gardasil for vaccines and gene therapies, improving 
vaccine efficacy and enabling targeted delivery of genetic materials.
 Johnson & Johnson: Johnson & Johnson applies polymer-based nanoparticles in products 
like Risperdal Consta for diseases like schizophrenia, improving drug stability and targeted 
delivery.
 Novartis: Novartis uses lipid-based technologies in products like Kisqali for breast cancer 
treatment, improving drug solubility and extending circulation times.
Developments in nanoparticle-based drug delivery by these companies lead to advancements in 
their product offerings, driving precision medicine and personalized therapies globally. Hence, this 
progress positions them as leaders in cutting-edge healthcare solutions.
As advancements in RNAi drug delivery accelerate, there is a rising demand for precise and effective 
therapeutic solutions. With increasing research and investment in innovative technologies, the RNA 
interference (RNAi) drug delivery market is estimated to experience developing growth during the 
forecast period.
Explore the market insights in this YouTube video by clicking here
Can’t find what you’re looking for? Talk to an expert NOW!
FAQs:
1. Which diseases are targeted by RNAi drug delivery therapies?
A: RNAi therapies target a wide range of diseases, including genetic disorders, viral 
infections, neurodegenerative diseases, and various types of cancer. These therapies 
aim to intervene at the genetic level to treat underlying causes of disease.
2. What are the current challenges in RNAi drug delivery development?
A: The challenges in RNAi drug delivery include optimizing the delivery of RNA 
molecules to specific tissues, mitigating immune responses to synthetic RNA, and 
ensuring their safety and efficacy in clinical settings. Ongoing research focuses on 
refining delivery systems to effectively address these hurdles.